23530-42-9

Usage

Uses

Used in Veterinary Medicine:
N-ISOPROPYL-2-NITROBENZENESULPHONAMIDE is used as an anti-inflammatory and analgesic agent for the treatment of various conditions in animals, such as arthritis, post-operative pain, and other musculoskeletal disorders. It is commonly prescribed by veterinarians for dogs and cats to manage pain and inflammation associated with these conditions.
Used in Pain Management for Animals:
N-ISOPROPYL-2-NITROBENZENESULPHONAMIDE is used as a pain management solution in animals to provide relief from discomfort and facilitate recovery from surgeries or injuries. It is available in different forms, including tablets, chewable tablets, and injectable solutions, to accommodate various administration methods and animal preferences.
Used under Veterinary Supervision:
N-ISOPROPYL-2-NITROBENZENESULPHONAMIDE is used under the guidance and supervision of a licensed veterinarian to ensure proper dosage and administration. This is crucial to guarantee the safety and effectiveness of the treatment while minimizing the risk of side effects.
Used with Caution in Animals with NSAID Allergies:
N-ISOPROPYL-2-NITROBENZENESULPHONAMIDE should not be used in animals with a history of allergic reactions to NSAIDs, as it may cause adverse side effects. Veterinarians must carefully consider the animal's medical history and potential risks before prescribing this medication.

InChI:InChI=1/C9H12N2O4S/c1-7(2)10-16(14,15)9-6-4-3-5-8(9)11(12)13/h3-7,10H,1-2H3

Upstream product

• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 75-31-0 isopropylamine 

Downstream Products

• 1365272-16-7 2-amino-N-isopropylbenzenesulfonamide hydrochloride 
• 761435-31-8 2-amino-N-isopropylbenzenesulfonamide 
• 863968-74-5 N-isopropyl-N-(1-methyl-1H-pyrrol-2-yl)-2-nitro-benzenesulfonamide 

Relevant academic research and scientific papers

Direct Synthesis of Allyl Amines with 2-Nitrosulfonamide Derivatives via the Tsuji-Trost Reaction

The Tsuji-Trost Reaction is a palladium-catalysed allylation of nucleophiles that consists in the reaction of a nitrogen, carbon or oxygen-based nucleophiles with an allylic substrate bearing a leaving group. Here we present the use of 2-nitrosulfonamide derivatives as nucleophile, which are reactive under mild conditions. 2-nitrosulfonyl groups are well-known dual protective activator groups easy to introduce in any type of amine substrates. The resulting 2-nitrosulfonamide derivatives are ideal substrates for the Tsuji-Trost reaction to afford a convenient and flexible access to primary and dissymmetric secondary allyl amines. The optimised procedure is flexible (for solvent, temperature, functional groups) and has been applied with good to excellent yield to access to a wide range of allyl amine derivatives.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Tweaking Subtype Selectivity and Agonist Efficacy at (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) Receptors in a Small Series of BnTetAMPA Analogues

A series of analogues of the (S)-2-Amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid (AMPA) receptor agonist BnTetAMPA (5b) were synthesized and characterized pharmacologically in radioligand binding assays at native and cloned AMPA receptors and functionally by two-electrode voltage clamp electrophysiology at the four homomeric AMPA receptors expressed in Xenopus laevis oocytes. The analogues 6 and 7 exhibit very different pharmacological profiles with binding affinity preference for the subtypes GluA1 and GluA3, respectively. X-ray crystal structures of three ligands (6, 7, and 8) in complex with the agonist binding domain (ABD) of GluA2 show that they induce full domain closure despite their low agonist efficacies. Trp767 in GluA2 ABD could be an important determinant for partial agonism of this compound series at AMPA receptors, since agonist efficacy also correlated with the location of the Trp767 side chain.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

Nickel-catalyzed regio- and enantioselective annulation reactions of 1,2,3,4-benzothiatriazine-1,1(2H)-dioxides with allenes

(Figure Presented) Extrusion of N2:1,2,3,4-Benzothiatriazine1,1 (2H)-dioxides reacted with alienes in the presence of a nickel (0)/(R)-quinap complex to produce a variety of substituted 3,4-dihydro-1,2-benzothiazine1,1 (2H)-dioxides in a regio- and enantioselective fashion. An intermediate nickelacycle was generated through denitrogenative activation of the triazo moiety which allowed the intermolecular incorporation of an aliene group. quinap = 1-(2diphenylphosphino-1-naphthyl)isoquinoline.

INHIBITORS OF FOCAL ADHESION KINASE

The invention provides inhibitors of focal adhesion kinase, an enzyme involved in the attachment of the cytoskeleton of a cell to an extracellular matrix, which has been implicated in processes such as cell migration, cell proliferation, and cell survival. The inhibitors are derivatives of a 5-substituted 2,4-diaminopyridine wherein the substituents are as defined herein. The invention also provides a method of using the inhibitors in treatment of cancer, and methods of preparation of the inhibitors by use of coupling reactions.